Share This Link

Using a 1.5-inch needle is inappropriate for a 2-month-old infant because the needle is excessively long for the infant’s muscle mass. An overly long needle increases the risk of striking bone or causing tissue injury. Infants typically require a shorter needle, usually 1 inch or less depending on size and body composition.

Inserting the needle at a 45° angle is incorrect for intramuscular injections. IM medications and vaccines should generally be administered at a 90° angle to ensure the medication reaches the muscle tissue. A 45° angle is more appropriate for subcutaneous injections, where medication is intended for adipose tissue rather than muscle.

Administering the vaccine at a specific rate such as 1 mL per 5 seconds is unnecessary and not a standard guideline for pediatric vaccine administration. Vaccines are typically injected steadily and smoothly without emphasis on timing. The priority is proper placement and minimizing discomfort rather than controlling administration speed.

The client’s room number is not an acceptable identifier because room assignments can change during hospitalization. Multiple clients may also occupy similar locations over time, increasing the risk of misidentification. Reliance on room number alone has been associated with preventable medication and treatment errors.

The client’s medical diagnosis is not an appropriate identifier because many clients may share the same condition or diagnosis. Diagnoses are not unique personal identifiers and can lead to confusion, particularly in units caring for patients with similar illnesses. Safe identification requires information specific to only one individual.

The client’s year of birth alone is insufficient because it is not unique enough to accurately identify a patient. Many individuals may share the same birth year, especially in large healthcare facilities. While date of birth may be used as one identifier when combined with another approved identifier, year of birth alone is inadequate.

Drowsiness is more commonly associated with the therapeutic or toxic effects of diazepam rather than withdrawal. Benzodiazepines produce central nervous system depression, leading to sedation and decreased alertness during use. Withdrawal instead results in increased neuronal excitability and heightened stimulation rather than excessive sleepiness.

Anorexia may occur in various medical or psychological conditions but is not one of the hallmark findings of benzodiazepine withdrawal. Withdrawal symptoms are primarily neurologic and autonomic in nature, resulting from rebound CNS activity. More characteristic manifestations include tremors, agitation, restlessness, and insomnia.

Hypotension is not typically associated with diazepam withdrawal. Instead, abrupt cessation often produces sympathetic nervous system stimulation, which can lead to elevated blood pressure, tachycardia, and diaphoresis. The physiologic response reflects loss of the medication’s calming and inhibitory effects on the CNS.

Acute asthma is not a direct contraindication to clopidogrel administration. Unlike some medications such as aspirin or nonsteroidal anti-inflammatory drugs, clopidogrel does not commonly trigger bronchospasm or worsen asthma symptoms. While overall respiratory status should still be monitored, asthma alone does not preclude use of this medication.

Stroke is not necessarily a contraindication and is often an indication for clopidogrel therapy, particularly in ischemic stroke prevention. The medication helps reduce platelet aggregation and lowers the risk of recurrent thrombotic cerebrovascular events. However, caution is required in cases of hemorrhagic stroke because of bleeding risk.

Hyperlipidemia is not a contraindication for clopidogrel and is commonly present in clients with peripheral vascular disease. In fact, clients with elevated lipid levels often benefit from antiplatelet therapy because they are at increased risk for atherosclerotic thrombosis. Management usually includes both lipid-lowering agents and antiplatelet medications.

Diphenhydramine is an antihistamine and does not significantly affect coagulation or interact with warfarin. It may cause sedation or anticholinergic effects but does not increase bleeding risk. Therefore, it does not require immediate reporting in the context of warfarin therapy.

Docusate sodium is a stool softener used to prevent constipation and has no known interaction with warfarin. It does not affect platelet function, clotting factors, or vitamin K metabolism. It is generally considered safe for clients receiving anticoagulant therapy.

Famotidine is an H2 receptor antagonist used to reduce gastric acid secretion and does not significantly interact with warfarin. In fact, it may be beneficial in reducing gastric irritation and ulcer risk, which can help lower the risk of gastrointestinal bleeding in some clients on anticoagulants.

Thyroxine (T4) is a thyroid hormone test and is not related to the mechanism or therapeutic effect of epoetin alfa. Epoetin alfa does not affect thyroid function, and T4 levels would not reflect changes in red blood cell production. Therefore, this test is not useful for evaluating medication effectiveness.

Aspartate aminotransferase (AST) is a liver enzyme used to assess hepatic function and is not directly influenced by epoetin alfa therapy. While liver function may be monitored in some clinical situations, AST does not provide information about red blood cell production or anemia correction.

Troponin is a cardiac biomarker used to detect myocardial injury such as myocardial infarction. It is unrelated to erythropoiesis or anemia management and does not reflect the therapeutic response to epoetin alfa. Monitoring troponin would only be relevant if cardiac ischemia is suspected.

Placing drops in the center of the eye is not the correct technique because ophthalmic medications should be instilled into the conjunctival sac, not directly onto the cornea. Direct corneal application can cause discomfort and reflex blinking, leading to medication loss. Proper placement ensures better absorption and effectiveness of Latanoprost.

Closing the eyes tightly after instillation is incorrect because it increases the risk of forcing medication out of the eye and reducing absorption. Tight squeezing can also increase intraocular pressure temporarily. Instead, gentle eye closure is recommended to allow proper distribution of the medication across the ocular surface.

An altered taste in the mouth is not a typical expected effect of latanoprost. While some ophthalmic medications may cause mild systemic effects, latanoprost is more commonly associated with local ocular effects such as iris pigmentation changes, eyelash growth, or eye irritation. Taste disturbances are not part of expected therapeutic outcomes or teaching priorities.

Diarrhea is a known gastrointestinal side effect of allopurinol but is generally mild and self-limiting. It does not usually indicate a serious hypersensitivity reaction or require urgent discontinuation of therapy unless severe or persistent. Supportive management such as hydration may be sufficient in most cases.

A metallic taste in the mouth can occur as a minor and non-threatening adverse effect of various medications, including allopurinol. This symptom is not associated with serious toxicity or immune-mediated reactions. It is typically temporary and does not require immediate provider notification unless accompanied by other concerning symptoms.

Nausea is a common and mild adverse effect associated with allopurinol use. It is usually transient and can often be managed with administration after meals or symptomatic relief measures. It does not typically indicate a severe allergic or toxic reaction requiring urgent reporting.